Piramal Pharma Q2 Results Review - Operating Performance Above Estimate; FY25 Guidance Intact: Motilal Oswal
With enhanced inquiries on the CDMO front at industry level in India, the brokerage believes the company is well poised to benefit from its differentiated capabilities and capacities.
from NDTV Profit https://ift.tt/0gOj72X
from NDTV Profit https://ift.tt/0gOj72X
Piramal Pharma Q2 Results Review - Operating Performance Above Estimate; FY25 Guidance Intact: Motilal Oswal
![Piramal Pharma Q2 Results Review - Operating Performance Above Estimate; FY25 Guidance Intact: Motilal Oswal]()
Reviewed by aamira sultan
on
October 25, 2024
Rating:
No comments: